Table 1.

Patient characteristics.

Before TCZ TherapyAt the End of Followup
PatientAge at Disease Onset, yrsDisease Duration, moPervious Immunosuppressive AgentsPD, mg/dayESR, mm/hCRP, mg/lPD, mg/dayESR, mm/hCRP, mg/lImproved LesionsStable LesionsWorsened LesionsNew LesionsActive Disease (NIH Criteria*)Months on TCZResponseCause of TCZ Withdrawal
124101MTX, MMF, AZA, IFX1076101015< 14522Yes17Persistence of TA activity, vascular progression
22366MTX, ADA, IFX, CYC, sirolimus7.534133.7514< 11410No36PR
33017AZA, MTX15311310411513Yes9Relapse at PD tapering and vascular progression
42767AZA, IFX, CTX, MTX, ADA, AKR, RTX, CYC15321225263610Yes10Relapse at PD tapering
61950MMF, CTX, minocycline, MTX5.038145.02< 411000No14CRCutaneous rash
72482AZA, CYC, MTX, sirolimus, IFX, ADA1540356.2242200No12CRRelapsing sinusitis and pneumonia
  • TCZ: tocilizumab; PD: prednisone daily dose; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CR: complete response; PR: partial response; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil; CYC: cyclosporine; CTX: cyclophosphamide; IFX: infliximab; ADA: adalimumab; AKR: anakinra; RTX: rituximab.